205 related articles for article (PubMed ID: 31732653)
1. A Small-Molecule Inhibitor Targeting TRIP13 Suppresses Multiple Myeloma Progression.
Wang Y; Huang J; Li B; Xue H; Tricot G; Hu L; Xu Z; Sun X; Chang S; Gao L; Tao Y; Xu H; Xie Y; Xiao W; Yu D; Kong Y; Chen G; Sun X; Lian F; Zhang N; Wu X; Mao Z; Zhan F; Zhu W; Shi J
Cancer Res; 2020 Feb; 80(3):536-548. PubMed ID: 31732653
[TBL] [Abstract][Full Text] [Related]
2. Design and synthesis of cantharidin derivative DCZ5418 as a TRIP13 inhibitor with anti-multiple myeloma activity in vitro and in vivo.
Dong S; Hu K; Shi Y; Wang G; Yu D; Zhao Y; Zhang H; Wang Y; Sun H; Xu Z; Jia Q; Li Y; Li Y; Li B; Shi J; Zhu W
Bioorg Med Chem Lett; 2024 Jan; 98():129590. PubMed ID: 38092072
[TBL] [Abstract][Full Text] [Related]
3. DCZ0415, a small-molecule inhibitor targeting TRIP13, inhibits EMT and metastasis via inactivation of the FGFR4/STAT3 axis and the Wnt/β-catenin pathway in colorectal cancer.
Agarwal S; Afaq F; Bajpai P; Kim HG; Elkholy A; Behring M; Chandrashekar DS; Diffalha SA; Khushman M; Sugandha SP; Varambally S; Manne U
Mol Oncol; 2022 Apr; 16(8):1728-1745. PubMed ID: 35194944
[TBL] [Abstract][Full Text] [Related]
4. TI17, a novel compound, exerts anti-MM activity by impairing Trip13 function of DSBs repair and enhancing DNA damage.
Chang S; Xiao W; Xie Y; Xu Z; Li B; Wang G; Hu K; Zhang Y; Zhou J; Song D; Zhu H; Wu X; Lu Y; Shi J; Zhu W
Cancer Med; 2023 Dec; 12(23):21321-21334. PubMed ID: 37942576
[TBL] [Abstract][Full Text] [Related]
5. The novel norcantharidin derivative DCZ5417 suppresses multiple myeloma progression by targeting the TRIP13-MAPK-YWHAE signaling pathway.
Wang Y; Dong S; Hu K; Xu L; Feng Q; Li B; Wang G; Chen G; Zhang B; Jia X; Xu Z; Gao X; Zhang H; Xie Y; Lu M; Chang S; Song D; Wu X; Jia Q; Zhu H; Zhou J; Zhu W; Shi J
J Transl Med; 2023 Nov; 21(1):858. PubMed ID: 38012658
[TBL] [Abstract][Full Text] [Related]
6. TRIP13 impairs mitotic checkpoint surveillance and is associated with poor prognosis in multiple myeloma.
Tao Y; Yang G; Yang H; Song D; Hu L; Xie B; Wang H; Gao L; Gao M; Xu H; Xu Z; Wu X; Zhang Y; Zhu W; Zhan F; Shi J
Oncotarget; 2017 Apr; 8(16):26718-26731. PubMed ID: 28157697
[TBL] [Abstract][Full Text] [Related]
7. Elevated TRIP13 drives the AKT/mTOR pathway to induce the progression of hepatocellular carcinoma via interacting with ACTN4.
Zhu MX; Wei CY; Zhang PF; Gao DM; Chen J; Zhao Y; Dong SS; Liu BB
J Exp Clin Cancer Res; 2019 Sep; 38(1):409. PubMed ID: 31533816
[TBL] [Abstract][Full Text] [Related]
8. Thyroid hormone receptor interactor 13 (TRIP13) overexpression associated with tumor progression and poor prognosis in lung adenocarcinoma.
Li W; Zhang G; Li X; Wang X; Li Q; Hong L; Shen Y; Zhao C; Gong X; Chen Y; Zhou J
Biochem Biophys Res Commun; 2018 May; 499(3):416-424. PubMed ID: 29567476
[TBL] [Abstract][Full Text] [Related]
9. Targeting of oncogenic AAA-ATPase TRIP13 reduces progression of pancreatic ductal adenocarcinoma.
Afaq F; Agarwal S; Bajpai P; Diffalha SA; Kim HG; Peter S; Khushman M; Chauhan SC; Mukherjee P; Varambally S; Manne U
Neoplasia; 2024 Jan; 47():100951. PubMed ID: 38039923
[TBL] [Abstract][Full Text] [Related]
10. Small molecule inhibitor screen identifies synergistic activity of the bromodomain inhibitor CPI203 and bortezomib in drug resistant myeloma.
Siegel MB; Liu SQ; Davare MA; Spurgeon SE; Loriaux MM; Druker BJ; Scott EC; Tyner JW
Oncotarget; 2015 Aug; 6(22):18921-32. PubMed ID: 26254279
[TBL] [Abstract][Full Text] [Related]
11. Melphalan and Exportin 1 Inhibitors Exert Synergistic Antitumor Effects in Preclinical Models of Human Multiple Myeloma.
Turner JG; Cui Y; Bauer AA; Dawson JL; Gomez JA; Kim J; Cubitt CL; Nishihori T; Dalton WS; Sullivan DM
Cancer Res; 2020 Dec; 80(23):5344-5354. PubMed ID: 33023948
[TBL] [Abstract][Full Text] [Related]
12. TRIP13 modulates protein deubiquitination and accelerates tumor development and progression of B cell malignancies.
Li C; Xia J; Franqui-Machin R; Chen F; He Y; Ashby TC; Teng F; Xu H; Liu D; Gai D; Johnson SK; van Rhee F; Janz S; Shaughnessy JD; Tricot G; Frech I; Zhan F
J Clin Invest; 2021 Jul; 131(14):. PubMed ID: 34061780
[TBL] [Abstract][Full Text] [Related]
13. TRIP13 promotes error-prone nonhomologous end joining and induces chemoresistance in head and neck cancer.
Banerjee R; Russo N; Liu M; Basrur V; Bellile E; Palanisamy N; Scanlon CS; van Tubergen E; Inglehart RC; Metwally T; Mani RS; Yocum A; Nyati MK; Castilho RM; Varambally S; Chinnaiyan AM; D'Silva NJ
Nat Commun; 2014 Jul; 5():4527. PubMed ID: 25078033
[TBL] [Abstract][Full Text] [Related]
14. High throughput chemical library screening identifies a novel p110-δ inhibitor that potentiates the anti-myeloma effect of bortezomib.
Malek E; Driscoll JJ
Oncotarget; 2016 Jun; 7(25):38523-38538. PubMed ID: 27229530
[TBL] [Abstract][Full Text] [Related]
15. Molecular mechanisms of assembly and TRIP13-mediated remodeling of the human Shieldin complex.
Xie W; Wang S; Wang J; de la Cruz MJ; Xu G; Scaltriti M; Patel DJ
Proc Natl Acad Sci U S A; 2021 Feb; 118(8):. PubMed ID: 33597306
[TBL] [Abstract][Full Text] [Related]
16. Upregulation of thyroid hormone receptor interactor 13 is associated with human hepatocellular carcinoma.
Ju L; Li X; Shao J; Lu R; Wang Y; Bian Z
Oncol Rep; 2018 Dec; 40(6):3794-3802. PubMed ID: 30542731
[TBL] [Abstract][Full Text] [Related]
17. Novel Protein Disulfide Isomerase Inhibitor with Anticancer Activity in Multiple Myeloma.
Vatolin S; Phillips JG; Jha BK; Govindgari S; Hu J; Grabowski D; Parker Y; Lindner DJ; Zhong F; Distelhorst CW; Smith MR; Cotta C; Xu Y; Chilakala S; Kuang RR; Tall S; Reu FJ
Cancer Res; 2016 Jun; 76(11):3340-50. PubMed ID: 27197150
[TBL] [Abstract][Full Text] [Related]
18. The histone deacetylase inhibitor LBH589 enhances the anti-myeloma effects of chemotherapy in vitro and in vivo.
Sanchez E; Shen J; Steinberg J; Li M; Wang C; Bonavida B; Chen H; Li ZW; Berenson JR
Leuk Res; 2011 Mar; 35(3):373-9. PubMed ID: 20650529
[TBL] [Abstract][Full Text] [Related]
19. Inducing Synergistic DNA Damage by TRIP13 and PARP1 Inhibitors Provides a Potential Treatment for Hepatocellular Carcinoma.
Xu H; Ma Z; Mo X; Chen X; Xu F; Wu F; Chen H; Zhou G; Xia H; Zhang C
J Cancer; 2022; 13(7):2226-2237. PubMed ID: 35517402
[TBL] [Abstract][Full Text] [Related]
20. Induction therapy in a multiple myeloma mouse model using a combination of AS101 and melphalan, and the activity of AS101 in a tumor microenvironment model.
Hayun M; Saida H; Albeck M; Peled A; Haran-Ghera N; Sredni B
Exp Hematol; 2009 May; 37(5):593-603. PubMed ID: 19375650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
